ABSTRACT

Fexofenadine hydrochloride (FEX) and montelukast sodium (MON) are often prescribed together for allergic rhinitis and airway disorders because they work well together. FEX is a second-generation H?- receptor antagonist. It offers non-sedative antihistaminic effects along with some anti-inflammatory benefits. MON is a cysteinyl leukotriene receptor antagonist, which helps reduce inflammation and bronchoconstriction caused by leukotrienes. Using both medications together provides better symptom control, especially for nasal congestion, compared to taking either one alone. Effective methods for estimating FEX and MON at the same time are important for ensuring quality in pharmaceuticals and monitoring therapy. Several methods have been reported, including UV spectrophotometry, stability-indicating assays, and reversed-phase high-performance liquid chromatography (RP-HPLC). UV methods are straightforward and environmentally friendly, but they often lack selectivity. On the other hand, RP-HPLC methods offer accuracy and reliability for stability studies, although they usually require toxic solvents and more resources. This review looks closely at the existing methods for analyzing FEX and MON together, focusing on sustainability. Green metrics like Analytical GREEnness (AGREE) and Green Analytical Procedure Index (GAPI) were used to evaluate eco-friendliness. The results show a trade-off between sensitivity and environmental impact, highlighting the need for greener yet reliable options. Keywords: Fexofenadine, Montelukast, UV spectrophotometry, HPLC, Green analytical tools, AGREE, GAPI
Publication date: 01/07/2026

https://www.ijbpas.com/pdf/2026/July/MS_IJBPAS_2026_10339.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.7.10339